Form 4: Adaptimmune Therapeutics Executive Acquires Options for Over 6 Million Ordinary Shares

Cintia Piccina, Chief Commercial Officer of Adaptimmune Therapeutics, reports the acquisition of options to purchase over 6 million ordinary shares.

Summary

• Cintia Piccina, the Chief Commercial Officer of Adaptimmune Therapeutics PLC, filed a Form 4.
• The form details the acquisition of options to purchase ordinary shares of Adaptimmune Therapeutics.
• Piccina acquired options to purchase 5,088,864 Ordinary Shares at an exercise price of $0.25 on March 18, 2024.
• These options are exercisable in installments, starting with 1,679,325 shares immediately and the remainder in monthly installments until March 2027.
• Additionally, Piccina acquired options to purchase 1,130,832 Ordinary Shares at an exercise price of $0.0013 on the same date.
• These options are exercisable in installments starting June 18, 2024, and annually until January 15, 2028.
• The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

Sentiment

Score: 6

Explanation: The document is a neutral regulatory filing. The acquisition of options by an executive could be seen as a slightly positive sign, but it's primarily an informational document.

Positives

• The acquisition of options by a key executive could be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in publicly traded companies. It reflects standard practices for incentivizing executives through equity-based compensation.

Comparison to Industry Standards

• Equity-based compensation, such as stock options, is a common practice among publicly traded biotechnology companies like Adaptimmune Therapeutics.
• Companies such as Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead) have used similar compensation strategies to align executive interests with shareholder value.
• The vesting schedules and exercise prices are generally in line with industry standards for executive compensation packages.

Stakeholder Impact

• Shareholders may view the executive's acquisition of options as a sign of confidence in the company's future performance.

Key Dates